Showing results (21-30 of 155) with videos related to
Sort By:
Pageof 16
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 29, 2017
Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung CancersChristos Chouaid, Laura Luciani, Katell LeLay, et al.Future Oncology (London, England)|May 1, 2020
Treatment sequence of first and second generation tyrosine kinase inhibitor followed by osimertinib in <i>EGFR</i>-mutated non-small-cell lung cancer: a real life studyNicolas Girard, Denis Moro-Sibilot, Stéphane Bouée, et al.Cardiovascular and Interventional Radiology|December 8, 2011
Endovascular treatment of malignant superior vena cava syndrome: results and predictive factors of clinical efficacyDorothée Fagedet, Frederic Thony, Jean-François Timsit, et al.Respiratory Medicine and Research|April 10, 2023
Impact of extended interval dosing of immune checkpoint inhibitors in lung cancer patients during the COVID-19 pandemicMarie Veron, Thomas Pierret, Maurice Pérol, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 11, 2011
Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French studyAnne McLeer-Florin, Denis Moro-Sibilot, Adrien Melis, et al.Lung Cancer (Amsterdam, Netherlands)|February 17, 2005
First line chemotherapy with gemcitabine in advanced non-small cell lung cancer elderly patients: a randomized phase II study of 3-week versus 4-week scheduleElisabeth Quoix, Jean-Luc Breton, Alain Ducoloné, et al.The European Respiratory Journal|October 18, 2014
Selection criteria for intensive care unit referral of lung cancer patients: a pilot studyAnne-Claire Toffart, Carola Alegria Pizarro, Carole Schwebel, et al.Oncology and Therapy|September 14, 2025
Real-World Use and Immunotherapy Rechallenge Outcomes with Nivolumab in Advanced Non-small Cell Lung Cancer in France: Interim Results of the LIST StudyBenoît Godbert, Elisa Gobbini, Chantal Decroisette, et al.Targeted Oncology|August 15, 2014
Rebiopsy during disease progression in patients treated by TKI for oncogene-addicted NSCLCCecile Bosc, Gilbert R Ferretti, Jacques Cadranel, et al.Journal for Immunotherapy of Cancer|March 19, 2021
Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxelDavid Gandara, Martin Reck, Denis Moro-Sibilot, et al.Pageof 16